Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
<h4>Background</h4>Lung cancer is the leading cause of cancer deaths worldwide. New diagnostics are needed to detect early stage lung cancer because it may be cured with surgery. However, most cases are diagnosed too late for curative surgery. Here we present a comprehensive clinical bio...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-12-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0015003&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849736110550286336 |
|---|---|
| author | Rachel M Ostroff William L Bigbee Wilbur Franklin Larry Gold Mike Mehan York E Miller Harvey I Pass William N Rom Jill M Siegfried Alex Stewart Jeffrey J Walker Joel L Weissfeld Stephen Williams Dom Zichi Edward N Brody |
| author_facet | Rachel M Ostroff William L Bigbee Wilbur Franklin Larry Gold Mike Mehan York E Miller Harvey I Pass William N Rom Jill M Siegfried Alex Stewart Jeffrey J Walker Joel L Weissfeld Stephen Williams Dom Zichi Edward N Brody |
| author_sort | Rachel M Ostroff |
| collection | DOAJ |
| description | <h4>Background</h4>Lung cancer is the leading cause of cancer deaths worldwide. New diagnostics are needed to detect early stage lung cancer because it may be cured with surgery. However, most cases are diagnosed too late for curative surgery. Here we present a comprehensive clinical biomarker study of lung cancer and the first large-scale clinical application of a new aptamer-based proteomic technology to discover blood protein biomarkers in disease.<h4>Methodology/principal findings</h4>We conducted a multi-center case-control study in archived serum samples from 1,326 subjects from four independent studies of non-small cell lung cancer (NSCLC) in long-term tobacco-exposed populations. Sera were collected and processed under uniform protocols. Case sera were collected from 291 patients within 8 weeks of the first biopsy-proven lung cancer and prior to tumor removal by surgery. Control sera were collected from 1,035 asymptomatic study participants with ≥ 10 pack-years of cigarette smoking. We measured 813 proteins in each sample with a new aptamer-based proteomic technology, identified 44 candidate biomarkers, and developed a 12-protein panel (cadherin-1, CD30 ligand, endostatin, HSP90α, LRIG3, MIP-4, pleiotrophin, PRKCI, RGM-C, SCF-sR, sL-selectin, and YES) that discriminates NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.<h4>Conclusions/significance</h4>This study is a significant advance in clinical proteomics in an area of high unmet clinical need. Our analysis exceeds the breadth and dynamic range of proteome interrogated of previously published clinical studies of broad serum proteome profiling platforms including mass spectrometry, antibody arrays, and autoantibody arrays. The sensitivity and specificity of our 12-biomarker panel improves upon published protein and gene expression panels. Separate verification of classifier performance provides evidence against over-fitting and is encouraging for the next development phase, independent validation. This careful study provides a solid foundation to develop tests sorely needed to identify early stage lung cancer. |
| format | Article |
| id | doaj-art-bfe3d7483e2f45f4a19b0f0fd5bed489 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2010-12-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-bfe3d7483e2f45f4a19b0f0fd5bed4892025-08-20T03:07:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-12-01512e1500310.1371/journal.pone.0015003Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.Rachel M OstroffWilliam L BigbeeWilbur FranklinLarry GoldMike MehanYork E MillerHarvey I PassWilliam N RomJill M SiegfriedAlex StewartJeffrey J WalkerJoel L WeissfeldStephen WilliamsDom ZichiEdward N Brody<h4>Background</h4>Lung cancer is the leading cause of cancer deaths worldwide. New diagnostics are needed to detect early stage lung cancer because it may be cured with surgery. However, most cases are diagnosed too late for curative surgery. Here we present a comprehensive clinical biomarker study of lung cancer and the first large-scale clinical application of a new aptamer-based proteomic technology to discover blood protein biomarkers in disease.<h4>Methodology/principal findings</h4>We conducted a multi-center case-control study in archived serum samples from 1,326 subjects from four independent studies of non-small cell lung cancer (NSCLC) in long-term tobacco-exposed populations. Sera were collected and processed under uniform protocols. Case sera were collected from 291 patients within 8 weeks of the first biopsy-proven lung cancer and prior to tumor removal by surgery. Control sera were collected from 1,035 asymptomatic study participants with ≥ 10 pack-years of cigarette smoking. We measured 813 proteins in each sample with a new aptamer-based proteomic technology, identified 44 candidate biomarkers, and developed a 12-protein panel (cadherin-1, CD30 ligand, endostatin, HSP90α, LRIG3, MIP-4, pleiotrophin, PRKCI, RGM-C, SCF-sR, sL-selectin, and YES) that discriminates NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.<h4>Conclusions/significance</h4>This study is a significant advance in clinical proteomics in an area of high unmet clinical need. Our analysis exceeds the breadth and dynamic range of proteome interrogated of previously published clinical studies of broad serum proteome profiling platforms including mass spectrometry, antibody arrays, and autoantibody arrays. The sensitivity and specificity of our 12-biomarker panel improves upon published protein and gene expression panels. Separate verification of classifier performance provides evidence against over-fitting and is encouraging for the next development phase, independent validation. This careful study provides a solid foundation to develop tests sorely needed to identify early stage lung cancer.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0015003&type=printable |
| spellingShingle | Rachel M Ostroff William L Bigbee Wilbur Franklin Larry Gold Mike Mehan York E Miller Harvey I Pass William N Rom Jill M Siegfried Alex Stewart Jeffrey J Walker Joel L Weissfeld Stephen Williams Dom Zichi Edward N Brody Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS ONE |
| title | Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. |
| title_full | Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. |
| title_fullStr | Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. |
| title_full_unstemmed | Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. |
| title_short | Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. |
| title_sort | unlocking biomarker discovery large scale application of aptamer proteomic technology for early detection of lung cancer |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0015003&type=printable |
| work_keys_str_mv | AT rachelmostroff unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT williamlbigbee unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT wilburfranklin unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT larrygold unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT mikemehan unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT yorkemiller unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT harveyipass unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT williamnrom unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT jillmsiegfried unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT alexstewart unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT jeffreyjwalker unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT joellweissfeld unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT stephenwilliams unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT domzichi unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer AT edwardnbrody unlockingbiomarkerdiscoverylargescaleapplicationofaptamerproteomictechnologyforearlydetectionoflungcancer |